Microarray analysis of bone marrow-derived macrophage cells treated with Kdo2-lipid A (KLA) and ATP

Search by fold change ratio | Search by KEGG pathway | Search by LIPID MAPS lipid pathway

Kdo2-Lipid A / ATP gene array data - treatment:control ratios

KEGG pathway: T cell receptor signaling pathway (mmu04660)

Legend:graph_icon: View data/graphs for replicates
Gene symbol    Time course plot Accession Description Treatment 15min 30min 1hr 2hr 4hr 8hr 20hr
1500003O
03Rik
KLA  ATP  ATP+KLA
 NM_019769 RIKEN cDNA 1500003O03 gene (1500003O03Rik), mRNA [NM_019769] KLA .92 .89 .89 .86 .85 .92 1.08
ATP 1.01 1.16 1.16 1.53 1.70 3.33 2.09
KLA/ATP .89 .97 .93 1.17 1.19 2.86 2.57
2010110P
09Rik
KLA  ATP  ATP+KLA
 NM_027363 RIKEN cDNA 2010110P09 gene (2010110P09Rik), mRNA [NM_027363] KLA .99 .98 1.02 .99 .94 1.01 1.01
ATP 1.04 1.05 .97 1.05 .95 .98 .95
KLA/ATP .93 1.00 1.02 .97 1.01 .96 .97
AK036998
KLA  ATP  ATP+KLA
 AK036998 adult female vagina cDNA, RIKEN full-length enriched library, clone:9930034M05 product:unclassifiable, full insert sequence. [AK036998] KLA 1.43 1.09 .89 .79 .96 .97 .71
ATP 1.04 1.04 .71 .64 .90 .82 .82
KLA/ATP 1.34 1.23 1.01 .89 1.10 .82 .75
AK088985
KLA  ATP  ATP+KLA
 AK088985 2 days neonate thymus thymic cells cDNA, RIKEN full-length enriched library, clone:E430034J06 product:unclassifiable, full insert sequence. [AK088985] KLA .99 1.07 .92 .88 .96 1.02 .91
ATP 1.03 .86 .92 .85 1.13 1.00 .93
KLA/ATP .95 1.08 .97 .85 .83 .96 .89
Akt1
KLA  ATP  ATP+KLA
 NM_009652 thymoma viral proto-oncogene 1 (Akt1), mRNA [NM_009652] KLA .80 .80 .75 .75 .71 .70 .82
ATP 1.00 1.02 .76 .85 .76 .68 .84
KLA/ATP .82 .80 .64 .68 .67 .61 .72
Akt2
KLA  ATP  ATP+KLA
 NM_007434 thymoma viral proto-oncogene 2 (Akt2), transcript variant 2, mRNA [NM_007434] KLA 1.45 1.49 1.81 1.61 1.83 1.17 .92
ATP 1.12 1.12 1.00 1.28 1.20 .94 1.06
KLA/ATP 1.48 1.70 1.69 1.58 1.57 1.32 1.27
Akt3
KLA  ATP  ATP+KLA
 NM_011785 thymoma viral proto-oncogene 3 (Akt3), mRNA [NM_011785] KLA 3.42 3.45 5.31 5.16 4.65 3.80 2.12
ATP 1.12 1.22 1.10 1.37 1.02 1.11 1.56
KLA/ATP 3.72 4.17 4.62 4.64 2.74 2.05 3.82
BB113440
KLA  ATP  ATP+KLA
 BB113440 gb|BB113440 RIKEN full-length enriched, adult male urinary bladder Mus musculus cDNA clone 9530041B19 3. [BB113440] KLA .94 .95 .94 .95 1.05 .99 1.05
ATP 1.03 1.07 1.79 1.71 1.51 1.12 1.06
KLA/ATP .95 1.11 1.27 1.15 1.05 1.14 1.25
Bcl10
KLA  ATP  ATP+KLA
 AK080820 adult male corpora quadrigemina cDNA, RIKEN full-length enriched library, clone:B230313B18 product:unclassifiable, full insert sequence [AK080820] KLA 1.44 1.52 1.23 1.38 1.54 1.25 1.08
ATP 1.31 1.35 1.59 1.40 3.05 2.29 .90
KLA/ATP 1.58 2.14 1.93 1.47 2.94 1.95 1.33
Bcl10
KLA  ATP  ATP+KLA
 NM_009740 B-cell leukemia/lymphoma 10 (Bcl10), mRNA [NM_009740] KLA 1.63 1.57 1.42 1.42 1.52 1.04 1.14
ATP 1.10 1.12 1.04 1.06 1.97 2.63 1.15
KLA/ATP 1.40 1.58 1.36 1.27 1.54 1.87 1.51
Card11
KLA  ATP  ATP+KLA
 AK002346 adult male kidney cDNA, RIKEN full-length enriched library, clone:0610008L17 product:CASPASE RECRUITMENT DOMAIN PROTEIN 11 (CARD-CONTAINING MAGUK PROTEIN 3) (CARMA 1) homolog [Homo sapiens], full insert sequence. [AK002346] KLA .83 .86 .89 .91 1.13 .99 .99
ATP .97 .93 .89 .93 .88 .89 .98
KLA/ATP .91 .87 .89 .86 .88 .92 1.01
Card11
KLA  ATP  ATP+KLA
 NM_175362 caspase recruitment domain family, member 11 (Card11), mRNA [NM_175362] KLA .33 .29 .31 .44 .71 1.30 1.45
ATP .84 .68 .79 .71 .38 .26 .47
KLA/ATP .33 .27 .40 .35 .38 .37 .85
Cbl
KLA  ATP  ATP+KLA
 NM_007619 Casitas B-lineage lymphoma (Cbl), mRNA [NM_007619] KLA 1.23 1.22 1.54 1.84 2.25 2.58 2.75
ATP 1.04 1.12 1.07 1.53 1.55 2.12 3.23
KLA/ATP 1.23 1.20 1.22 1.44 1.31 1.88 6.28
Cblb
KLA  ATP  ATP+KLA
 AK045005 9.5 days embryo parthenogenote cDNA, RIKEN full-length enriched library, clone:B130018P07 product:hypothetical protein, full insert sequence. [AK045005] KLA 1.16 1.11 1.15 1.10 1.16 .98 .93
ATP 1.16 1.23 .98 1.28 1.34 .73 1.55
KLA/ATP 1.26 1.60 1.64 1.23 1.01 .91 1.05
Cblb
KLA  ATP  ATP+KLA
 AK084162 12 days embryo eyeball cDNA, RIKEN full-length enriched library, clone:D230004I05 product:unclassifiable, full insert sequence. [AK084162] KLA .97 .98 1.02 1.01 .84 1.02 1.03
ATP 1.03 1.02 .98 1.09 1.05 .96 .96
KLA/ATP 1.07 .95 .91 .98 .98 1.01 1.00
Cblc
KLA  ATP  ATP+KLA
 NM_023224 Casitas B-lineage lymphoma c (Cblc), mRNA [NM_023224] KLA 1.02 .98 1.01 1.02 1.00 .99 1.05
ATP .94 .95 .97 1.04 .99 .97 .99
KLA/ATP 1.00 1.01 .96 .97 .94 .92 .99
Cd247
KLA  ATP  ATP+KLA
 AK016078 adult male testis cDNA, RIKEN full-length enriched library, clone:4930549J05 product:unclassifiable, full insert sequence. [AK016078] KLA .95 1.01 .98 1.08 1.01 .95 .99
ATP 1.01 1.05 1.02 .99 1.02 1.01 1.07
KLA/ATP .97 .99 1.00 1.05 1.01 .96 .98
Cd247
KLA  ATP  ATP+KLA
 NM_001113391 CD247 antigen (Cd247), transcript variant zeta, mRNA [NM_001113391] KLA 3.06 3.63 3.61 2.90 3.04 1.93 1.28
ATP 1.07 1.03 1.19 1.21 1.39 1.42 1.12
KLA/ATP 3.09 3.74 2.98 2.90 2.14 2.13 2.41
Cd247
KLA  ATP  ATP+KLA
 NM_031162 CD247 antigen (Cd247), transcript variant eta, mRNA [NM_031162] KLA 1.29 1.35 1.39 1.26 1.35 1.16 1.17
ATP .99 1.01 1.04 1.03 1.08 1.05 1.02
KLA/ATP 1.34 1.42 1.24 1.33 1.18 1.18 1.23
Cd28
KLA  ATP  ATP+KLA
 NM_007642 CD28 antigen (Cd28), mRNA [NM_007642] KLA .52 .51 .45 .50 .36 .33 .18
ATP 1.11 1.26 1.08 1.25 1.99 1.42 2.08
KLA/ATP .51 .51 .58 .60 .56 .53 .38
Cd3d
KLA  ATP  ATP+KLA
 NM_013487 CD3 antigen, delta polypeptide (Cd3d), mRNA [NM_013487] KLA 1.01 1.05 1.00 .95 .98 1.03 1.02
ATP 1.02 .94 1.08 .99 .99 .94 1.05
KLA/ATP .93 .91 .99 .98 .96 .96 1.04
Cd3e
KLA  ATP  ATP+KLA
 NM_007648 CD3 antigen, epsilon polypeptide (Cd3e), mRNA [NM_007648] KLA 1.21 1.25 1.29 1.22 1.29 1.32 1.13
ATP .98 1.00 1.10 1.11 1.10 1.19 1.11
KLA/ATP 1.24 1.30 1.32 1.30 1.22 1.19 1.10
Cd3g
KLA  ATP  ATP+KLA
 NM_009850 CD3 antigen, gamma polypeptide (Cd3g), mRNA [NM_009850] KLA 1.05 1.01 .96 1.01 1.02 .99 .99
ATP .94 .97 .99 .99 .95 1.02 1.07
KLA/ATP .95 .92 1.08 1.03 1.01 1.01 .99
Cd4
KLA  ATP  ATP+KLA
 NM_013488 CD4 antigen (Cd4), mRNA [NM_013488] KLA .99 1.02 1.02 1.03 1.01 1.06 1.09
ATP 1.00 1.02 1.00 1.05 .96 .99 1.04
KLA/ATP 1.03 1.01 1.03 1.06 .97 .98 .98
Cd4
KLA  ATP  ATP+KLA
 X04836 gb|Mouse mRNA for T-cell surface glycoprotein CD4 (L3T4) [X04836] KLA .98 .91 .94 .96 .89 .92 1.03
ATP 1.11 1.07 1.02 .95 .90 .92 .88
KLA/ATP 1.04 1.00 1.01 .97 .90 1.02 .89
Cd40lg
KLA  ATP  ATP+KLA
 NM_011616 CD40 ligand (Cd40lg), mRNA [NM_011616] KLA 1.03 1.07 1.02 .98 1.06 1.06 1.03
ATP .95 .92 .99 1.06 1.02 1.04 1.07
KLA/ATP 1.00 1.01 .93 1.04 .94 1.01 .98
Cd8a
KLA  ATP  ATP+KLA
 NM_001081110 CD8 antigen, alpha chain (Cd8a), mRNA [NM_001081110] KLA 1.02 1.03 1.04 1.04 1.07 1.03 1.02
ATP 1.01 .98 .99 1.03 1.01 1.00 .99
KLA/ATP 1.02 1.01 1.04 1.03 1.06 1.06 1.00
Cd8b1
KLA  ATP  ATP+KLA
 M17534 gb|Mouse T-cell membrane glycoprotein (Ly-3) mRNA, complete cds. [M17534] KLA 1.04 1.06 1.11 1.12 1.07 1.06 .95
ATP 1.00 1.07 .97 .97 .96 1.05 .98
KLA/ATP .96 1.02 1.07 1.03 1.05 .95 .97
Cdc42
KLA  ATP  ATP+KLA
 NM_009861 cell division cycle 42 homolog (S. cerevisiae) (Cdc42), mRNA [NM_009861] KLA 1.04 1.01 1.02 1.04 1.12 1.21 1.12
ATP 1.07 1.10 1.04 1.06 1.02 .95 1.14
KLA/ATP .94 1.04 1.01 .97 .95 1.02 1.25
Cdk4
KLA  ATP  ATP+KLA
 NM_009870 cyclin-dependent kinase 4 (Cdk4), mRNA [NM_009870] KLA .66 .72 .65 .55 .46 .50 .71
ATP 1.03 1.02 .53 .65 .66 .63 .75
KLA/ATP .78 .61 .31 .42 .44 .62 .43
Chuk
KLA  ATP  ATP+KLA
 NM_007700 conserved helix-loop-helix ubiquitous kinase (Chuk), mRNA [NM_007700] KLA 1.32 1.42 1.41 1.17 1.32 1.22 1.40
ATP 1.22 1.30 1.18 .97 1.02 1.00 1.37
KLA/ATP 1.56 1.61 1.21 1.09 .83 .84 1.17
Csf2
KLA  ATP  ATP+KLA
 NM_009969 colony stimulating factor 2 (granulocyte-macrophage) (Csf2), mRNA [NM_009969] KLA 1.44 1.53 1.38 1.37 1.15 1.21 1.14
ATP 1.01 1.02 1.85 9.73 2.64 1.90 1.14
KLA/ATP 1.49 1.84 2.14 2.80 1.67 1.36 1.35
Ctla4
KLA  ATP  ATP+KLA
 NM_009843 cytotoxic T-lymphocyte-associated protein 4 (Ctla4), mRNA [NM_009843] KLA 1.00 1.04 1.01 1.01 .97 1.01 1.09
ATP 1.01 .98 1.06 .96 .96 .98 1.03
KLA/ATP 1.05 1.06 1.02 .90 .99 .99 1.02
Dlg1
KLA  ATP  ATP+KLA
 AK031364 13 days embryo male testis cDNA, RIKEN full-length enriched library, clone:6030413K05 product:discs, large homolog 1 (Drosophila), full insert sequence. [AK031364] KLA .92 .85 .88 .82 .95 .91 .98
ATP 1.11 1.01 .90 .87 1.03 .93 .92
KLA/ATP .94 .93 .80 .81 1.01 .90 .87
Dlg1
KLA  ATP  ATP+KLA
 NM_007862 discs, large homolog 1 (Drosophila) (Dlg1), mRNA [NM_007862] KLA 1.17 1.11 1.13 1.05 .89 .91 1.05
ATP .98 .97 1.13 1.12 .90 .96 .91
KLA/ATP 1.24 1.11 1.14 1.02 .80 .83 .80
Fos
KLA  ATP  ATP+KLA
 NM_010234 FBJ osteosarcoma oncogene (Fos), mRNA [NM_010234] KLA .42 .33 .64 .61 .71 .85 .71
ATP 3.48 5.46 23.78 25.22 1.71 2.36 1.50
KLA/ATP .90 1.74 5.97 8.62 1.28 2.42 4.52
Fyn
KLA  ATP  ATP+KLA
 U70324 Fyn(T) (L-fyn(T)) mRNA, complete cds. [U70324] KLA 1.23 1.27 1.31 1.27 1.31 .87 .48
ATP .88 .71 .66 .75 .90 1.28 .51
KLA/ATP 1.12 1.01 .94 .84 1.25 1.51 .53
Grap2
KLA  ATP  ATP+KLA
 AK030809 adult male thymus cDNA, RIKEN full-length enriched library, clone:5830410K04 product:monocytic adaptor, full insert sequence [AK030809] KLA 1.05 .98 .96 .95 .93 .95 .94
ATP 1.05 1.07 .99 1.02 .99 1.03 1.07
KLA/ATP .95 .93 .90 .94 1.00 .93 .97
Grap2
KLA  ATP  ATP+KLA
 NM_010815 GRB2-related adaptor protein 2 (Grap2), mRNA [NM_010815] KLA 1.07 .97 1.01 1.01 1.00 1.05 1.02
ATP 1.00 .96 .99 .97 1.02 .95 .87
KLA/ATP 1.06 .95 .94 .97 .91 .92 .99
Grb2
KLA  ATP  ATP+KLA
 NM_008163 growth factor receptor bound protein 2 (Grb2), mRNA [NM_008163] KLA .92 .88 .90 1.27 1.43 1.22 1.00
ATP 1.02 .83 .51 .42 .92 .70 .57
KLA/ATP .84 .77 .61 .56 1.56 1.49 .52
Grb2
KLA  ATP  ATP+KLA
 U07617 Grb2 adaptor protein (grb2) mRNA, complete cds. [U07617] KLA .83 .80 .95 1.13 1.38 1.36 1.06
ATP .84 .74 .51 .41 .82 .74 .59
KLA/ATP .77 .70 .57 .54 1.49 1.39 .53
Gsk3b
KLA  ATP  ATP+KLA
 NM_019827 glycogen synthase kinase 3 beta (Gsk3b), mRNA [NM_019827] KLA 1.06 1.03 1.11 1.01 1.26 1.28 1.26
ATP 1.18 1.27 1.15 2.07 2.37 2.32 1.67
KLA/ATP 1.15 1.21 .98 1.50 1.67 2.50 2.99
Hras1
KLA  ATP  ATP+KLA
 NM_008284 Harvey rat sarcoma virus oncogene 1 (Hras1), mRNA [NM_008284] KLA .79 .82 .77 .82 .94 1.03 1.07
ATP 1.01 .95 .69 .83 .79 1.12 1.15
KLA/ATP .84 .77 .61 .65 .82 1.00 1.05
Icos
KLA  ATP  ATP+KLA
 AK030827 adult male thymus cDNA, RIKEN full-length enriched library, clone:5830414M16 product:inducible T-cell co-stimulator, full insert sequence [AK030827] KLA .99 .91 .97 .99 .94 .90 .78
ATP 1.06 .97 1.03 .88 .90 .91 .79
KLA/ATP .92 .99 .98 .97 .95 .90 .80
Icos
KLA  ATP  ATP+KLA
 NM_017480 inducible T-cell co-stimulator (Icos), mRNA [NM_017480] KLA 1.01 .96 .86 .95 .92 .91 .84
ATP .99 1.05 1.00 .98 .96 .97 .86
KLA/ATP .95 .98 .94 1.00 .96 .88 .87
Ifng
KLA  ATP  ATP+KLA
 NM_008337 interferon gamma (Ifng), mRNA [NM_008337] KLA 1.05 1.02 1.01 1.01 1.01 1.04 1.00
ATP 1.00 1.01 1.01 .98 .97 1.04 1.03
KLA/ATP 1.01 1.01 1.06 1.10 1.24 1.10 1.04
Ikbkb
KLA  ATP  ATP+KLA
 NM_010546 inhibitor of kappaB kinase beta (Ikbkb), mRNA [NM_010546] KLA 1.88 2.10 2.14 1.83 1.73 1.31 1.19
ATP .81 .74 .55 .49 .59 1.05 .96
KLA/ATP 1.86 1.73 1.39 1.12 .89 1.17 1.24
Ikbkg
KLA  ATP  ATP+KLA
 AK042138 3 days neonate thymus cDNA, RIKEN full-length enriched library, clone:A630062P04 product:unclassifiable, full insert sequence. [AK042138] KLA .92 .87 .78 .78 .87 .88 .62
ATP .84 .71 .80 .50 1.15 2.33 .61
KLA/ATP .72 .69 .74 .48 1.06 1.97 .68
Ikbkg
KLA  ATP  ATP+KLA
 NM_010547 inhibitor of kappaB kinase gamma (Ikbkg), transcript variant 1, mRNA [NM_010547] KLA 1.51 1.63 1.74 1.83 1.83 1.73 1.72
ATP .80 .79 .82 .75 .66 2.58 2.37
KLA/ATP 1.43 1.42 1.17 1.04 .71 1.54 3.17
Ikbkg
KLA  ATP  ATP+KLA
 NM_178590 inhibitor of kappaB kinase gamma (Ikbkg), transcript variant 2, mRNA [NM_178590] KLA .84 .93 .86 .91 1.03 .89 .88
ATP 1.03 .98 .68 .56 .51 .93 .68
KLA/ATP .89 .81 .55 .52 .41 .67 .65
Il10
KLA  ATP  ATP+KLA
 NM_010548 interleukin 10 (Il10), mRNA [NM_010548] KLA 17.59 18.64 22.22 23.06 11.83 8.27 2.07
ATP 1.86 3.22 7.72 20.51 25.86 8.38 1.01
KLA/ATP 17.91 23.49 34.53 34.48 20.98 12.03 8.17
Il2
KLA  ATP  ATP+KLA
 NM_008366 interleukin 2 (Il2), mRNA [NM_008366] KLA .96 .97 .96 1.00 .97 .97 .99
ATP 1.04 1.02 1.00 1.03 .97 .98 .97
KLA/ATP 1.01 .98 .97 1.00 .97 .97 .96
Il4
KLA  ATP  ATP+KLA
 NM_021283 interleukin 4 (Il4), mRNA [NM_021283] KLA .94 .95 .91 .94 .91 .94 1.07
ATP 1.02 1.06 1.05 1.22 1.12 1.10 1.26
KLA/ATP .92 .96 .93 1.08 .98 1.03 1.18
Il5
KLA  ATP  ATP+KLA
 NM_010558 interleukin 5 (Il5), mRNA [NM_010558] KLA 1.10 1.11 1.10 .98 1.01 .98 .97
ATP .94 1.04 1.08 .92 .97 1.02 1.03
KLA/ATP .98 .92 1.12 1.03 1.02 1.00 1.03
Itk
KLA  ATP  ATP+KLA
 AK037554 16 days neonate thymus cDNA, RIKEN full-length enriched library, clone:A130026F16 product:IL2-inducible T-cell kinase, full insert sequence. [AK037554] KLA .89 .95 .91 .89 .94 .76 .70
ATP 1.07 .97 .98 .88 .69 .59 .70
KLA/ATP .98 .96 .84 .86 .72 .60 .49
Itk
KLA  ATP  ATP+KLA
 NM_010583 IL2-inducible T-cell kinase (Itk), mRNA [NM_010583] KLA 1.10 1.22 1.29 1.17 1.15 1.10 1.18
ATP 1.00 1.01 1.04 .97 1.00 .93 1.00
KLA/ATP 1.28 1.22 1.16 1.06 .95 1.00 1.15
Jun
KLA  ATP  ATP+KLA
 NM_010591 Jun oncogene (Jun), mRNA [NM_010591] KLA 1.08 .96 1.09 1.09 .75 .88 .81
ATP 1.26 1.48 4.45 8.73 4.02 1.16 1.99
KLA/ATP 1.12 1.38 3.52 5.17 3.32 .49 1.42
Kras
KLA  ATP  ATP+KLA
 NM_021284 v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (Kras), mRNA [NM_021284] KLA .53 .49 .40 .42 .49 .95 1.05
ATP .98 1.01 1.16 1.17 1.39 1.29 1.74
KLA/ATP .50 .47 .50 .56 1.00 1.24 1.58
Lat
KLA  ATP  ATP+KLA
 NM_010689 linker for activation of T cells (Lat), mRNA [NM_010689] KLA .91 .95 .94 .87 .76 .63 .48
ATP .97 .99 1.01 1.50 1.59 1.49 1.00
KLA/ATP .91 1.04 .93 1.15 1.11 .96 .65
Lck
KLA  ATP  ATP+KLA
 NM_010693 lymphocyte protein tyrosine kinase (Lck), mRNA [NM_010693] KLA 18.74 17.97 23.64 20.20 17.34 8.29 1.29
ATP 1.00 1.04 1.28 1.30 1.48 2.55 1.44
KLA/ATP 21.76 24.22 23.73 23.04 22.66 12.06 2.90
Lcp2
KLA  ATP  ATP+KLA
 NM_010696 lymphocyte cytosolic protein 2 (Lcp2), mRNA [NM_010696] KLA 9.10 9.37 9.29 7.53 9.33 5.54 4.23
ATP 1.25 1.38 .95 1.73 2.80 2.13 1.06
KLA/ATP 10.47 10.89 6.89 11.38 3.88 1.80 2.82
Malt1
KLA  ATP  ATP+KLA
 AK172081 activated spleen cDNA, RIKEN full-length enriched library, clone:F830035G05 product:unclassifiable, full insert sequence [AK172081] KLA 8.85 8.52 6.90 6.44 8.01 3.16 3.02
ATP 1.37 1.55 2.57 6.23 6.73 5.82 1.27
KLA/ATP 9.01 10.69 14.85 12.51 4.33 4.50 6.89
Malt1
KLA  ATP  ATP+KLA
 NM_172833 mucosa associated lymphoid tissue lymphoma translocation gene 1 (Malt1), mRNA [NM_172833] KLA 17.74 16.14 15.00 9.66 9.87 4.22 3.54
ATP 1.20 1.19 2.20 5.12 10.20 8.16 1.25
KLA/ATP 19.07 18.41 21.75 20.07 13.32 7.72 8.40
Map2k1
KLA  ATP  ATP+KLA
 NM_008927 mitogen-activated protein kinase kinase 1 (Map2k1), mRNA [NM_008927] KLA 1.82 2.00 2.31 2.03 2.51 2.20 1.51
ATP .99 1.14 .81 .87 .90 1.57 1.11
KLA/ATP 1.90 2.03 1.50 1.93 1.63 2.03 2.06
Map2k2
KLA  ATP  ATP+KLA
 NM_023138 mitogen-activated protein kinase kinase 2 (Map2k2), mRNA [NM_023138] KLA .96 1.01 1.09 .99 1.11 1.15 1.42
ATP 1.07 1.05 .74 .86 1.04 1.16 1.21
KLA/ATP 1.14 1.03 .68 .78 .85 1.01 1.20
Map2k7
KLA  ATP  ATP+KLA
 BC070467 mitogen activated protein kinase kinase 7, mRNA (cDNA clone MGC:96654 IMAGE:30615302), complete cds [BC070467] KLA .77 .79 .88 .77 .97 .96 1.27
ATP 1.11 1.26 .93 1.19 1.13 1.45 1.16
KLA/ATP .89 .88 .59 .89 .86 1.32 1.28
Map2k7
KLA  ATP  ATP+KLA
 NM_001042557 mitogen-activated protein kinase kinase 7 (Map2k7), transcript variant 1, mRNA [NM_001042557] KLA .96 .95 1.02 .96 .95 1.09 1.19
ATP 1.02 1.07 .88 .97 .93 1.10 1.17
KLA/ATP 1.01 .99 .80 .87 .76 1.21 1.16
Map3k14
KLA  ATP  ATP+KLA
 NM_016896 mitogen-activated protein kinase kinase kinase 14 (Map3k14), mRNA [NM_016896] KLA .32 .30 .40 .52 1.08 1.14 .94
ATP 1.18 1.24 1.13 .85 .82 .84 .99
KLA/ATP .33 .30 .34 .50 1.02 .84 1.43
Map3k7
KLA  ATP  ATP+KLA
 NM_172688 mitogen-activated protein kinase kinase kinase 7 (Map3k7), mRNA [NM_172688] KLA 1.48 1.49 1.51 1.24 1.21 1.19 1.61
ATP 1.10 1.16 1.03 1.03 1.12 1.61 1.61
KLA/ATP 1.43 1.56 1.05 1.15 .85 1.48 1.76
Map3k8
KLA  ATP  ATP+KLA
 D13759 cot mRNA for proto-oncogene protein, complete cds. [D13759] KLA 11.38 11.64 13.24 13.31 10.92 5.26 3.31
ATP 1.36 1.09 1.75 6.27 10.51 3.58 1.60
KLA/ATP 12.58 11.57 8.93 14.10 13.92 4.98 4.09
Mapk1
KLA  ATP  ATP+KLA
 NM_001038663 mitogen-activated protein kinase 1 (Mapk1), transcript variant 2, mRNA [NM_001038663] KLA .97 1.03 .93 .86 .79 1.01 1.04
ATP .96 1.18 1.01 1.13 .84 1.04 1.16
KLA/ATP .99 .99 .84 .87 .63 .96 1.26
Mapk1
KLA  ATP  ATP+KLA
 NM_011949 mitogen-activated protein kinase 1 (Mapk1), transcript variant 1, mRNA [NM_011949] KLA .88 .80 .80 .73 .75 .76 .65
ATP .97 .96 1.06 .88 .90 .68 .48
KLA/ATP .82 .81 .78 .65 .64 .64 .45
Mapk11
KLA  ATP  ATP+KLA
 NM_011161 mitogen-activated protein kinase 11 (Mapk11), mRNA [NM_011161] KLA 1.28 1.30 1.41 1.46 1.58 1.29 .98
ATP .96 .95 .89 .82 .79 1.09 .85
KLA/ATP 1.44 1.42 1.32 1.23 1.23 .74 .66
Mapk12
KLA  ATP  ATP+KLA
 NM_013871 mitogen-activated protein kinase 12 (Mapk12), mRNA [NM_013871] KLA .94 .86 .87 .81 .77 .68 .49
ATP .97 .83 .92 .90 .86 .90 .51
KLA/ATP .91 .89 .88 .85 1.12 1.14 .53
Mapk13
KLA  ATP  ATP+KLA
 NM_011950 mitogen-activated protein kinase 13 (Mapk13), mRNA [NM_011950] KLA 1.22 1.21 1.35 1.26 1.24 1.13 1.01
ATP 1.08 1.00 1.20 1.20 1.13 1.22 1.39
KLA/ATP 1.22 1.27 1.30 1.30 1.21 1.11 1.47
Mapk14
KLA  ATP  ATP+KLA
 NM_011951 mitogen-activated protein kinase 14 (Mapk14), mRNA [NM_011951] KLA .70 .70 .62 .54 .67 .88 1.11
ATP 1.03 .98 .87 .69 .48 .78 .66
KLA/ATP .74 .68 .52 .46 .38 .45 .62
Mapk3
KLA  ATP  ATP+KLA
 NM_011952 mitogen-activated protein kinase 3 (Mapk3), mRNA [NM_011952] KLA .81 .85 .88 .72 .79 .73 .90
ATP 1.13 1.30 .92 1.48 1.08 .68 1.03
KLA/ATP 1.01 1.01 .66 1.13 .77 .77 1.16
Mapk9
KLA  ATP  ATP+KLA
 NM_016961 mitogen-activated protein kinase 9 (Mapk9), transcript variant 2, mRNA [NM_016961] KLA 1.28 1.37 1.59 1.60 1.61 1.43 1.38
ATP 1.03 .99 .74 .71 .79 1.20 1.01
KLA/ATP 1.53 1.30 1.07 .99 .83 1.10 1.40
Mapk9
KLA  ATP  ATP+KLA
 NM_207692 mitogen-activated protein kinase 9 (Mapk9), transcript variant 1, mRNA [NM_207692] KLA 1.39 1.53 1.69 1.69 1.55 1.44 1.51
ATP .95 .92 .75 .85 .70 1.46 1.17
KLA/ATP 1.37 1.35 .99 1.18 .91 1.22 1.62
Mm.13157
2
KLA  ATP  ATP+KLA
 134949023 Unknown KLA 1.04 1.01 .96 .95 .95 1.00 .99
ATP .98 1.02 .99 1.07 .97 .96 1.00
KLA/ATP .96 .88 .91 1.00 1.02 .98 1.05
Mm.15898
1
KLA  ATP  ATP+KLA
 142388182 Unknown KLA .25 .22 .31 .50 .85 1.11 .83
ATP 1.02 .94 1.31 .76 .73 .96 .92
KLA/ATP .24 .22 .34 .38 1.16 .96 1.23
Mm.21036
1
KLA  ATP  ATP+KLA
 158508719 Unknown KLA 1.12 1.15 1.09 1.20 1.18 1.33 1.23
ATP 1.05 1.18 1.10 1.41 1.26 1.25 1.23
KLA/ATP 1.22 1.40 1.22 1.54 1.24 1.28 1.49
Mm.21312
8
KLA  ATP  ATP+KLA
 141801344 Unknown KLA .96 .95 .83 .77 .52 .99 1.32
ATP .80 .82 1.09 .80 .83 1.19 1.46
KLA/ATP .78 .92 .98 .62 .71 .94 1.41
Mm.24185
7
KLA  ATP  ATP+KLA
 142347489 Unknown KLA 1.18 1.09 1.27 1.24 1.14 1.18 1.15
ATP 1.10 1.02 1.13 1.16 1.04 1.03 1.11
KLA/ATP 1.17 1.19 1.29 1.21 1.10 1.02 1.19
Mm.25381
9
KLA  ATP  ATP+KLA
 118130676 Unknown KLA 1.81 1.88 1.96 1.62 1.89 2.44 1.56
ATP .92 .91 1.24 1.01 1.16 2.06 1.95
KLA/ATP 1.62 1.86 1.86 1.41 1.89 2.37 1.97
Mm.25500
3
KLA  ATP  ATP+KLA
 161484596 Unknown KLA .35 .34 .35 .34 .22 .19 .10
ATP 1.09 1.27 1.13 1.29 2.25 1.66 2.22
KLA/ATP .38 .36 .39 .40 .49 .42 .32
Mm.26687
1
KLA  ATP  ATP+KLA
 80978931 Unknown KLA .67 .63 .70 .83 1.66 1.43 1.54
ATP 1.20 1.24 1.22 1.26 1.80 .81 1.02
KLA/ATP .63 .56 .83 1.06 1.26 .70 1.34
Mm.27970
KLA  ATP  ATP+KLA
 13994135 Unknown KLA 1.06 1.11 1.16 1.07 1.11 1.08 .95
ATP 1.02 1.09 1.05 1.05 .94 1.16 1.32
KLA/ATP 1.10 1.19 1.11 1.04 1.08 1.02 1.33
Mm.33138
9
KLA  ATP  ATP+KLA
 158508469 Unknown KLA .80 .79 .81 .82 .72 .64 .50
ATP .95 .85 .56 .48 .30 .33 .46
KLA/ATP .71 .64 .50 .41 .33 .32 .42
Mm.33314
8
KLA  ATP  ATP+KLA
 118129874 Unknown KLA 1.04 1.03 1.05 1.08 1.05 1.02 1.00
ATP .95 1.08 .99 .91 .96 1.03 1.07
KLA/ATP .99 1.00 1.02 .98 1.00 .98 1.10
Mm.44463
KLA  ATP  ATP+KLA
 118129851 Unknown KLA 1.01 .98 .97 1.02 .93 1.06 1.05
ATP .97 1.01 1.04 1.06 1.02 1.08 .97
KLA/ATP 1.02 1.06 .95 1.04 1.09 1.14 1.03
Mm.81698
KLA  ATP  ATP+KLA
 158937287 Unknown KLA .95 1.02 1.04 .98 1.01 1.04 1.08
ATP 1.00 1.03 .97 1.00 1.03 .98 .96
KLA/ATP 1.07 1.00 .94 .98 1.03 1.05 .97
Mm.874
KLA  ATP  ATP+KLA
 6754317 Unknown KLA 24.98 24.87 26.43 39.61 12.88 8.64 1.63
ATP 1.97 3.50 11.05 28.47 38.30 10.44 .65
KLA/ATP 23.45 29.37 58.52 51.77 30.64 14.61 8.63
Nck1
KLA  ATP  ATP+KLA
 ENSMUST00000116522 ens|non-catalytic region of tyrosine kinase adaptor protein 1 [Source:RefSeq_peptide;Acc:NP_035008] [ENSMUST00000116522] KLA 1.59 1.56 1.35 1.27 1.34 1.04 1.21
ATP 1.25 1.32 1.00 1.18 1.79 1.25 .96
KLA/ATP 2.00 2.22 1.41 1.34 1.21 1.35 1.27
Nck1
KLA  ATP  ATP+KLA
 NM_010878 non-catalytic region of tyrosine kinase adaptor protein 1 (Nck1), mRNA [NM_010878] KLA 6.52 5.82 4.53 2.34 1.72 1.14 1.26
ATP .91 .92 1.07 .68 1.72 2.07 1.15
KLA/ATP 5.62 5.96 5.77 2.46 1.63 1.99 1.86
Nck2
KLA  ATP  ATP+KLA
 NM_010879 non-catalytic region of tyrosine kinase adaptor protein 2 (Nck2), mRNA [NM_010879] KLA 1.72 1.26 1.32 1.00 1.46 1.78 1.50
ATP 1.08 1.05 .84 .59 1.28 1.26 1.17
KLA/ATP 1.68 1.27 1.14 .80 .94 .99 1.91
Nfat5
KLA  ATP  ATP+KLA
 AK172011 activated spleen cDNA, RIKEN full-length enriched library, clone:F830029B05 product:nuclear factor of activated T-cells 5, full insert sequence. [AK172011] KLA .94 .90 .93 .93 1.28 1.27 1.16
ATP .95 .76 1.13 1.27 1.93 2.21 1.18
KLA/ATP .85 .84 1.10 .92 1.53 1.63 1.66
Nfat5
KLA  ATP  ATP+KLA
 NM_018823 nuclear factor of activated T-cells 5 (Nfat5), transcript variant b, mRNA [NM_018823] KLA .95 1.01 .99 1.03 1.08 1.13 1.19
ATP 1.05 1.22 1.67 1.98 1.74 1.38 1.17
KLA/ATP 1.03 1.07 1.34 1.38 1.30 1.19 1.40
Nfat5
KLA  ATP  ATP+KLA
 NM_133957 nuclear factor of activated T-cells 5 (Nfat5), transcript variant a, mRNA [NM_133957] KLA 1.07 1.07 1.00 .96 1.42 1.36 1.51
ATP 1.15 1.19 1.81 4.36 6.34 3.49 1.12
KLA/ATP 1.27 1.08 1.87 2.72 3.58 3.05 2.07
Nfatc1
KLA  ATP  ATP+KLA
 NM_016791 nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 1 (Nfatc1), transcript variant 1, mRNA [NM_016791] KLA .71 .66 .68 .62 .63 .67 .81
ATP 1.12 1.29 1.15 1.21 .83 .63 1.25
KLA/ATP .78 .79 .65 .74 .59 .45 .92
Nfatc1
KLA  ATP  ATP+KLA
 NM_198429 nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 1 (Nfatc1), transcript variant 2, mRNA [NM_198429] KLA .49 .41 .50 .43 .50 .78 .69
ATP 1.05 .81 .84 .54 .60 .38 .69
KLA/ATP .46 .37 .45 .32 .62 .39 .61
Nfatc2
KLA  ATP  ATP+KLA
 AK081853 16 days embryo head cDNA, RIKEN full-length enriched library, clone:C130082H17 product:nuclear factor of activated T-cells, cytoplasmic 2, full insert sequence. [AK081853] KLA .56 .52 .59 .61 .78 .78 .66
ATP 1.19 1.27 .67 .65 .62 .53 .79
KLA/ATP .52 .49 .71 .57 .65 .52 .53
Nfatc2
KLA  ATP  ATP+KLA
 NM_001037177 nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 2 (Nfatc2), transcript variant 2, mRNA [NM_001037177] KLA .84 .79 .74 .82 .89 .98 .80
ATP 1.06 1.13 1.01 .87 .86 .83 1.10
KLA/ATP .76 .72 .89 .84 .84 .81 .84
Nfatc2
KLA  ATP  ATP+KLA
 NM_010899 nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 2 (Nfatc2), transcript variant 1, mRNA [NM_010899] KLA .90 .91 .86 .91 .86 1.07 1.00
ATP 1.08 1.11 1.45 1.04 .88 .85 1.18
KLA/ATP .85 .89 .92 .89 .93 .84 1.13
Nfatc3
KLA  ATP  ATP+KLA
 AK084848 13 days embryo lung cDNA, RIKEN full-length enriched library, clone:D430001G08 product:nuclear factor of activated T-cells, cytoplasmic 3, full insert sequence. [AK084848] KLA 1.08 .96 .98 1.00 .98 1.03 .98
ATP 1.00 1.03 .93 .92 .92 1.11 .98
KLA/ATP 1.01 .87 1.10 .97 .96 .96 .99
Nfatc3
KLA  ATP  ATP+KLA
 NM_010901 nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 3 (Nfatc3), mRNA [NM_010901] KLA .77 .68 .67 .77 .85 .90 1.04
ATP 1.01 .95 .89 .70 .70 .92 .98
KLA/ATP .77 .66 .64 .59 .82 .90 .90
Nfatc4
KLA  ATP  ATP+KLA
 AK014164 13 days embryo head cDNA, RIKEN full-length enriched library, clone:3110041H08 product:nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 4, full insert sequence. [AK014164] KLA .90 .92 .91 1.00 .99 .98 .95
ATP .90 1.03 .96 .98 .95 .97 1.00
KLA/ATP .95 .87 1.00 .98 .96 .96 .92
Nfatc4
KLA  ATP  ATP+KLA
 NM_023699 nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 4 (Nfatc4), mRNA [NM_023699] KLA 1.28 1.38 1.44 1.58 1.40 1.41 1.46
ATP 1.03 1.06 1.23 1.24 1.32 1.40 1.41
KLA/ATP 1.30 1.38 1.47 1.28 1.38 1.40 1.63
Nfkb1
KLA  ATP  ATP+KLA
 BC050841 nuclear factor of kappa light chain gene enhancer in B-cells 1, p105, mRNA (cDNA clone IMAGE:6392793), complete cds. [BC050841] KLA 5.81 4.96 4.77 3.21 3.37 2.00 1.71
ATP 1.39 1.52 3.25 12.63 13.64 4.80 1.08
KLA/ATP 7.21 8.69 19.53 23.93 11.70 2.85 2.01
Nfkb1
KLA  ATP  ATP+KLA
 M57999 gb|Mouse transcription factor NF-kappa-B DNA binding subunit mRNA, complete cds. [M57999] KLA 8.55 7.87 7.35 6.13 3.51 1.85 1.38
ATP .98 .96 1.21 3.06 5.29 4.67 .69
KLA/ATP 7.32 7.20 8.71 10.82 5.55 2.77 1.54
Nfkbia
KLA  ATP  ATP+KLA
 NM_010907 nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha (Nfkbia), mRNA [NM_010907] KLA 18.65 18.46 13.63 17.88 14.25 9.17 7.92
ATP .91 1.09 7.11 32.39 17.44 10.49 1.72
KLA/ATP 15.57 17.66 15.73 23.91 13.83 10.73 9.48
Nfkbib
KLA  ATP  ATP+KLA
 NM_010908 nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, beta (Nfkbib), mRNA [NM_010908] KLA 4.63 4.69 4.36 4.27 4.23 2.52 2.17
ATP 1.11 1.22 1.55 4.23 4.93 3.66 1.76
KLA/ATP 4.71 5.41 4.58 7.08 6.20 4.73 4.11
Nfkbie
KLA  ATP  ATP+KLA
 NM_008690 nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, epsilon (Nfkbie), mRNA [NM_008690] KLA 5.87 5.26 4.28 4.30 4.38 3.56 2.69
ATP .92 1.04 1.55 1.83 3.57 8.04 2.35
KLA/ATP 5.07 5.19 5.86 4.34 3.56 8.64 9.00
Nras
KLA  ATP  ATP+KLA
 NM_010937 neuroblastoma ras oncogene (Nras), mRNA [NM_010937] KLA 1.20 1.22 1.27 1.20 1.09 .91 .84
ATP .98 .91 .69 .61 .59 .67 .78
KLA/ATP 1.22 1.14 .97 .79 .73 .61 .72
Pak1
KLA  ATP  ATP+KLA
 NM_011035 p21 (CDKN1A)-activated kinase 1 (Pak1), mRNA [NM_011035] KLA .72 .77 .79 .71 .67 .73 .95
ATP 1.10 1.07 .99 1.15 1.27 .62 .51
KLA/ATP .85 .83 .73 .76 .76 .55 .33
Pak2
KLA  ATP  ATP+KLA
 NM_177326 p21 (CDKN1A)-activated kinase 2 (Pak2), mRNA [NM_177326] KLA 1.23 1.24 1.26 1.17 1.19 1.09 1.13
ATP 1.04 1.01 .65 .58 .82 1.18 1.45
KLA/ATP 1.26 1.26 .78 .72 .71 .95 1.44
Pak3
KLA  ATP  ATP+KLA
 NM_008778 p21 (CDKN1A)-activated kinase 3 (Pak3), mRNA [NM_008778] KLA 1.06 1.02 1.03 1.00 1.06 1.01 1.01
ATP 1.05 1.01 1.03 .97 .98 1.08 1.07
KLA/ATP 1.00 .99 .99 1.03 1.00 1.01 1.08
Pak4
KLA  ATP  ATP+KLA
 NM_027470 p21 (CDKN1A)-activated kinase 4 (Pak4), mRNA [NM_027470] KLA 1.41 1.51 1.62 1.57 1.88 1.26 1.06
ATP 1.13 1.15 1.04 1.21 1.73 1.45 1.03
KLA/ATP 1.58 1.60 1.31 1.65 1.84 1.64 1.40
Pak6
KLA  ATP  ATP+KLA
 AK028788 10 days neonate skin cDNA, RIKEN full-length enriched library, clone:4732456M09 product:p21 (CDKN1A)-activated kinase 6, full insert sequence. [AK028788] KLA 1.38 1.33 1.40 1.45 1.42 1.49 1.20
ATP .95 .93 1.15 1.21 1.21 1.32 1.10
KLA/ATP 1.33 1.38 1.55 1.44 1.57 1.45 1.36
Pak7
KLA  ATP  ATP+KLA
 AK077967 13 days embryo male testis cDNA, RIKEN full-length enriched library, clone:6030481C12 product:hypothetical protein, full insert sequence. [AK077967] KLA 1.00 1.01 1.07 1.02 .99 1.01 1.05
ATP .93 .95 1.03 1.01 1.02 .92 1.00
KLA/ATP 1.04 1.01 .99 1.04 .99 1.06 1.02
Pdcd1
KLA  ATP  ATP+KLA
 NM_008798 programmed cell death 1 (Pdcd1), mRNA [NM_008798] KLA 1.31 1.46 1.48 1.45 1.46 1.24 1.11
ATP .99 1.04 1.12 1.11 1.02 .97 1.12
KLA/ATP 1.37 1.37 1.22 1.51 1.41 1.48 1.57
Pdk1
KLA  ATP  ATP+KLA
 AK165090 2 days pregnant adult female ovary cDNA, RIKEN full-length enriched library, clone:E330005M21 product:hypothetical protein, full insert sequence. [AK165090] KLA .86 .77 .71 .67 .45 .29 .35
ATP 1.06 .88 1.21 .72 .60 .26 .15
KLA/ATP .81 .74 .97 .57 .51 .22 .09
Pdk1
KLA  ATP  ATP+KLA
 NM_172665 pyruvate dehydrogenase kinase, isoenzyme 1 (Pdk1), nuclear gene encoding mitochondrial protein, mRNA [NM_172665] KLA .92 .94 .91 .79 .63 .46 .51
ATP .95 1.03 1.06 1.02 .63 .31 .37
KLA/ATP .88 .91 .91 .89 .62 .31 .27
Pik3ca
KLA  ATP  ATP+KLA
 ENSMUST00000108243 ens|Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha isoform (EC 2.7.1.153) (PI3-kinase p110 subunit alpha) (PtdIns-3- kinase p110) (PI3K). [Source:Uniprot/SWISSPROT;Acc:P42337] [ENSMUST00000108243] KLA 1.07 1.01 .91 .90 .98 .96 .86
ATP 1.03 .87 1.12 .63 1.22 1.86 .60
KLA/ATP 1.05 .82 .91 .61 1.17 1.26 .63
Pik3ca
KLA  ATP  ATP+KLA
 NM_008839 phosphatidylinositol 3-kinase, catalytic, alpha polypeptide (Pik3ca), mRNA [NM_008839] KLA 1.15 1.11 1.05 .82 .99 1.03 1.27
ATP .98 1.00 .79 .75 .96 1.32 1.10
KLA/ATP 1.10 .98 .64 .72 .80 1.20 1.41
Pik3cb
KLA  ATP  ATP+KLA
 NM_029094 phosphatidylinositol 3-kinase, catalytic, beta polypeptide (Pik3cb), mRNA [NM_029094] KLA 1.06 1.06 1.03 .73 .68 .98 1.69
ATP 1.04 1.21 .95 1.02 .85 .93 1.73
KLA/ATP 1.15 1.27 .73 .83 .58 .81 1.81
Pik3cd
KLA  ATP  ATP+KLA
 NM_008840 phosphatidylinositol 3-kinase catalytic delta polypeptide (Pik3cd), transcript variant 1, mRNA [NM_008840] KLA 2.28 2.42 3.10 4.17 3.35 2.31 1.34
ATP 1.02 .91 .99 .63 .30 .67 .80
KLA/ATP 2.14 2.23 2.70 1.51 1.17 .85 .72
Pik3cd
KLA  ATP  ATP+KLA
 U86587 phosphatidylinositol 3-kinase catalytic subunit p110 delta mRNA, complete cds. [U86587] KLA 2.21 2.24 3.71 3.17 3.67 2.66 1.48
ATP 1.00 1.03 .93 .96 .46 .75 .97
KLA/ATP 2.27 2.32 1.97 2.02 1.01 .99 .98
Pik3cg
KLA  ATP  ATP+KLA
 NM_020272 phosphoinositide-3-kinase, catalytic, gamma polypeptide (Pik3cg), mRNA [NM_020272] KLA .53 .53 .61 .64 .97 .86 .79
ATP 1.01 1.13 .88 .89 .52 .53 .53
KLA/ATP .58 .53 .43 .60 .40 .43 .62
Pik3r1
KLA  ATP  ATP+KLA
 NM_001077495 phosphatidylinositol 3-kinase, regulatory subunit, polypeptide 1 (p85 alpha) (Pik3r1), transcript variant 2, mRNA [NM_001077495] KLA 1.05 1.07 1.03 1.00 1.01 1.20 .85
ATP .97 1.02 1.48 1.42 1.76 1.33 1.23
KLA/ATP 1.11 1.12 1.06 1.17 1.24 .99 1.12
Pik3r2
KLA  ATP  ATP+KLA
 NM_008841 phosphatidylinositol 3-kinase, regulatory subunit, polypeptide 2 (p85 beta) (Pik3r2), mRNA [NM_008841] KLA .50 .50 .48 .43 .46 .66 .75
ATP .78 .68 .45 .43 .28 .57 1.37
KLA/ATP .49 .38 .32 .33 .38 .67 1.10
Pik3r3
KLA  ATP  ATP+KLA
 NM_181585 phosphatidylinositol 3 kinase, regulatory subunit, polypeptide 3 (p55) (Pik3r3), mRNA [NM_181585] KLA 1.59 1.49 1.37 1.17 1.05 1.55 1.41
ATP 1.12 1.00 1.33 1.70 2.01 2.37 2.02
KLA/ATP 1.63 1.54 1.58 1.70 2.43 2.68 1.92
Pik3r5
KLA  ATP  ATP+KLA
 NM_177320 phosphoinositide-3-kinase, regulatory subunit 5, p101 (Pik3r5), mRNA [NM_177320] KLA 3.57 3.58 4.16 3.54 4.11 2.59 2.39
ATP 1.08 1.08 .93 1.67 3.11 1.88 1.34
KLA/ATP 3.91 3.70 3.30 3.80 2.70 2.04 3.00
Ppp3ca
KLA  ATP  ATP+KLA
 NM_008913 protein phosphatase 3, catalytic subunit, alpha isoform (Ppp3ca), mRNA [NM_008913] KLA .76 .85 .81 .85 .73 .70 .52
ATP .96 .78 .55 .46 .31 .33 .48
KLA/ATP .74 .64 .52 .42 .37 .36 .45
Ppp3cb
KLA  ATP  ATP+KLA
 AK135203 12 days embryo male wolffian duct includes surrounding region cDNA, RIKEN full-length enriched library, clone:6720421K10 product:protein phosphatase 3, catalytic subunit, beta isoform, full insert sequence. [AK135203] KLA 1.74 1.57 1.91 1.59 1.47 1.26 1.40
ATP 1.17 1.03 1.30 1.00 .81 .62 1.37
KLA/ATP 1.68 1.70 1.91 1.37 1.09 .47 1.13
Ppp3cb
KLA  ATP  ATP+KLA
 AK171904 activated spleen cDNA, RIKEN full-length enriched library, clone:F830018L06 product:Protein phosphatase 3 catalytic subunit beta3 (EC 3.1.3.16) (Serine [AK171904] KLA 1.29 1.29 1.21 1.15 1.22 1.13 1.28
ATP .90 .86 .80 .98 .94 .73 .92
KLA/ATP 1.06 1.03 .77 1.04 .92 .68 .90
Ppp3cb
KLA  ATP  ATP+KLA
 NM_008914 protein phosphatase 3, catalytic subunit, beta isoform (Ppp3cb), mRNA [NM_008914] KLA 1.21 1.29 1.38 1.24 1.29 1.08 1.23
ATP 1.15 1.31 1.09 1.29 .86 .60 .64
KLA/ATP 1.33 1.40 1.04 1.28 .79 .58 .73
Ppp3cc
KLA  ATP  ATP+KLA
 AK037563 16 days neonate thymus cDNA, RIKEN full-length enriched library, clone:A130026K22 product:unclassifiable, full insert sequence [AK037563] KLA 1.27 1.18 1.21 1.15 1.01 .92 1.36
ATP .96 1.09 1.10 1.03 .85 1.06 1.47
KLA/ATP 1.17 1.24 1.07 1.13 .91 .88 1.36
Ppp3cc
KLA  ATP  ATP+KLA
 NM_008915 protein phosphatase 3, catalytic subunit, gamma isoform (Ppp3cc), mRNA [NM_008915] KLA 1.64 1.81 1.79 1.35 .90 .70 1.31
ATP .90 .90 1.13 .93 .86 1.40 1.60
KLA/ATP 1.45 1.62 1.74 1.47 1.04 1.01 1.31
Ppp3r1
KLA  ATP  ATP+KLA
 NM_024459 protein phosphatase 3, regulatory subunit B, alpha isoform (calcineurin B, type I) (Ppp3r1), mRNA [NM_024459] KLA 1.02 1.17 .93 1.27 1.15 1.30 1.30
ATP .97 .95 .77 .91 .99 1.18 1.10
KLA/ATP 1.12 1.04 .88 1.00 1.10 1.10 1.07
Ppp3r2
KLA  ATP  ATP+KLA
 NM_001004025 protein phosphatase 3, regulatory subunit B, alpha isoform (calcineurin B, type II) (Ppp3r2), mRNA [NM_001004025] KLA 1.03 1.05 1.06 1.08 1.12 1.05 1.04
ATP 1.00 1.02 1.04 1.04 .99 .99 1.01
KLA/ATP 1.04 1.12 1.03 1.09 1.00 .99 1.00
Prkcq
KLA  ATP  ATP+KLA
 AK085546 0 day neonate kidney cDNA, RIKEN full-length enriched library, clone:D630039J01 product:protein kinase C, theta, full insert sequence [AK085546] KLA .98 .99 1.01 1.00 .95 .98 .97
ATP 1.06 .98 1.02 1.00 .99 .99 1.04
KLA/ATP .91 1.01 .84 1.02 1.03 1.00 1.03
Prkcq
KLA  ATP  ATP+KLA
 NM_008859 protein kinase C, theta (Prkcq), mRNA [NM_008859] KLA 1.04 1.07 1.00 1.06 1.02 .91 .87
ATP 1.06 .97 .97 .99 .94 1.00 .89
KLA/ATP 1.09 1.00 1.15 1.14 .98 1.07 .96
Ptpn6
KLA  ATP  ATP+KLA
 NM_001077705 protein tyrosine phosphatase, non-receptor type 6 (Ptpn6), transcript variant 2, mRNA [NM_001077705] KLA .87 .90 1.03 1.05 1.83 1.96 2.34
ATP 1.06 1.09 .94 1.08 .51 .34 1.04
KLA/ATP .98 .93 .71 .95 .67 .64 1.44
Ptpn6
KLA  ATP  ATP+KLA
 NM_013545 protein tyrosine phosphatase, non-receptor type 6 (Ptpn6), transcript variant 1, mRNA [NM_013545] KLA 1.24 1.20 1.46 1.42 2.43 2.27 2.10
ATP 1.18 1.20 1.10 1.49 .80 .58 1.09
KLA/ATP 1.36 1.42 1.27 1.66 1.12 .87 1.46
Ptpn6
KLA  ATP  ATP+KLA
 S63763 gb|me/Hcph (mev)=viable motheaten/hematopoietic cell protein-tyrosine phosphatase {insertion} [mice, mRNA Partial Mutant, 120 nt]. [S63763] KLA 1.06 1.03 1.12 1.14 1.11 1.01 1.09
ATP 1.03 .97 .96 .90 .89 1.17 1.76
KLA/ATP 1.07 1.00 1.03 .98 1.00 1.29 1.44
Ptprc
KLA  ATP  ATP+KLA
 AK088215 2 days neonate thymus thymic cells cDNA, RIKEN full-length enriched library, clone:E430007G18 product:protein tyrosine phosphatase, receptor type, C, full insert sequence. [AK088215] KLA 2.15 1.93 2.11 1.83 2.08 1.72 1.51
ATP .95 .84 .65 .50 1.79 .82 .77
KLA/ATP 2.01 1.68 1.50 .80 1.16 .73 1.14
Ptprc
KLA  ATP  ATP+KLA
 NM_011210 protein tyrosine phosphatase, receptor type, C (Ptprc), transcript variant 2, mRNA [NM_011210] KLA 2.06 2.00 2.21 2.29 2.20 1.90 1.86
ATP 1.02 .99 1.23 .82 1.01 1.68 .86
KLA/ATP 1.89 2.00 2.40 1.52 1.24 1.01 1.20
Raf1
KLA  ATP  ATP+KLA
 AK036317 16 days neonate cerebellum cDNA, RIKEN full-length enriched library, clone:9630056E02 product:v-raf-1 leukemia viral oncogene 1, full insert sequence. [AK036317] KLA 1.47 1.34 1.55 1.29 1.59 1.32 1.46
ATP 1.05 .98 .54 .63 3.32 2.07 1.01
KLA/ATP 1.57 1.33 .79 .96 2.26 1.38 1.35
Raf1
KLA  ATP  ATP+KLA
 NM_029780 v-raf-leukemia viral oncogene 1 (Raf1), mRNA [NM_029780] KLA 1.65 1.64 1.93 1.77 1.77 1.72 1.81
ATP .95 .96 .83 .80 2.22 2.92 1.19
KLA/ATP 1.68 1.64 1.39 1.32 1.85 2.50 2.06
Rasgrp1
KLA  ATP  ATP+KLA
 NM_011246 RAS guanyl releasing protein 1 (Rasgrp1), mRNA [NM_011246] KLA 6.54 6.48 7.17 6.75 10.11 12.90 17.38
ATP 1.18 1.35 1.31 1.32 1.76 2.47 1.30
KLA/ATP 5.86 7.13 6.00 5.09 3.36 5.58 14.25
Rela
KLA  ATP  ATP+KLA
 NM_009045 v-rel reticuloendotheliosis viral oncogene homolog A (avian) (Rela), mRNA [NM_009045] KLA 2.05 2.05 2.07 1.75 1.83 1.58 1.33
ATP 1.03 1.08 1.10 1.44 1.61 2.48 1.05
KLA/ATP 2.17 2.27 2.05 2.47 1.93 2.35 2.02
Rhoa
KLA  ATP  ATP+KLA
 NM_016802 ras homolog gene family, member A (Rhoa), mRNA [NM_016802] KLA .93 1.00 1.07 .97 1.08 1.06 1.02
ATP .93 .88 .49 .61 .63 .78 1.05
KLA/ATP .94 .92 .59 .63 .61 .78 1.12
Sos1
KLA  ATP  ATP+KLA
 NM_009231 Son of sevenless homolog 1 (Drosophila) (Sos1), mRNA [NM_009231] KLA 2.36 2.40 3.42 3.15 2.78 1.81 1.71
ATP .99 1.00 .99 1.15 1.14 1.25 1.24
KLA/ATP 2.41 2.26 1.95 2.44 1.47 1.66 1.37
Sos2
KLA  ATP  ATP+KLA
 XM_127051 gb|PREDICTED: Mus musculus Son of sevenless homolog 2 (Drosophila) (Sos2), mRNA [XM_127051] KLA .81 .77 .79 .92 1.04 1.06 1.20
ATP 1.00 1.00 1.09 .79 .68 .81 .94
KLA/ATP .77 .69 .71 .60 .64 .77 1.07
Tec
KLA  ATP  ATP+KLA
 NM_001113460 cytoplasmic tyrosine kinase, Dscr28C related (Drosophila) (Tec), transcript variant 1, mRNA [NM_001113460] KLA .41 .41 .51 .46 .47 .83 .68
ATP .94 .91 .87 1.00 1.05 .71 1.42
KLA/ATP .43 .42 .43 .38 .54 .93 1.46
Tnf
KLA  ATP  ATP+KLA
 NM_013693 tumor necrosis factor (Tnf), mRNA [NM_013693] KLA 13.35 12.76 10.71 9.03 10.64 7.39 8.32
ATP 2.01 2.48 8.27 19.20 9.72 4.09 1.49
KLA/ATP 12.72 15.76 12.73 17.34 5.10 3.61 6.07
Vav1
KLA  ATP  ATP+KLA
 NM_011691 vav 1 oncogene (Vav1), mRNA [NM_011691] KLA .79 .83 .98 1.17 1.97 2.42 2.26
ATP 1.06 1.02 .88 1.01 1.34 .82 1.36
KLA/ATP .88 .85 .73 .78 1.25 1.47 2.17
Vav2
KLA  ATP  ATP+KLA
 BC053060 vav 2 oncogene, mRNA (cDNA clone MGC:62363 IMAGE:5704852), complete cds [BC053060] KLA .73 .58 .55 1.16 .76 1.35 1.75
ATP .99 .89 .79 .82 .67 .85 1.09
KLA/ATP .64 .63 .61 .65 .66 .80 1.23
Vav2
KLA  ATP  ATP+KLA
 NM_009500 vav 2 oncogene (Vav2), mRNA [NM_009500] KLA .98 1.05 .98 .99 1.02 1.36 1.43
ATP 1.07 1.06 .96 1.01 .89 .95 1.08
KLA/ATP 1.04 1.05 .98 1.03 .88 .99 1.13
Vav3
KLA  ATP  ATP+KLA
 NM_020505 vav 3 oncogene (Vav3), transcript variant 1, mRNA [NM_020505] KLA .95 .94 .86 .87 .82 .66 .56
ATP 1.06 1.09 .81 1.05 .80 .75 .85
KLA/ATP 1.00 .84 .62 .85 .74 .56 .74
Zap70
KLA  ATP  ATP+KLA
 NM_009539 zeta-chain (TCR) associated protein kinase (Zap70), mRNA [NM_009539] KLA .94 .88 .84 .86 1.01 .92 .94
ATP 1.02 .99 .87 .87 1.58 .98 .96
KLA/ATP .94 .82 .83 .77 1.09 .93 1.02